Janet Woodcock, acting FDA commissioner (AP Images)

Eli Lil­ly’s Covid-19 drug bam­lanivimab is no longer dis­trib­uted in 3 states be­cause of a vari­ant, Wood­cock says

The US gov­ern­ment is no longer dis­trib­ut­ing Eli Lil­ly’s bam­lanivimab in­to Cal­i­for­nia, Ari­zona and Neva­da be­cause of the preva­lence of a vi­ral vari­ant that is not sus­cep­ti­ble to the mon­o­clon­al an­ti­body, FDA act­ing com­mis­sion­er Janet Wood­cock told physi­cians tak­ing part in a we­bi­nar with the Amer­i­can Med­ical As­so­ci­a­tion on Wednes­day.

Wood­cock did not elab­o­rate fur­ther on the vari­ant or the de­ci­sion to halt the dis­tri­b­u­tion, but over­all, the FDA re­mains unique­ly po­si­tioned to screen the mon­o­clon­als against the dif­fer­ent vari­ants, Wood­cock added, and that’s been pre­dic­tive of how and where the treat­ments will work.

A Lil­ly spokesper­son told End­points News in a state­ment: “We rec­og­nize the U.S. gov­ern­ment has made the de­ci­sion to no longer al­low di­rect or­der­ing of bam­lanivimab alone in Cal­i­for­nia, Ari­zona and Neva­da due to con­cerns about the preva­lence of the ‘Cal­i­for­nia’ vari­ant, with the spe­cif­ic L452R sub­sti­tu­tion found in B.1.429/B.1.427 lin­eages (a.k.a. 20C/CAL.20C). Im­por­tant­ly, pre­clin­i­cal da­ta from our labs demon­strate that the com­bi­na­tion of bam­lanivimab and ete­se­vimab main­tains its neu­tral­iz­ing ef­fect against this vari­ant, specif­i­cal­ly.”

Over­all, Wood­cock ac­knowl­edged that the ini­tial roll­out of the mon­o­clon­al an­ti­bod­ies “wasn’t the great­est” be­cause it was cen­tered on a dis­tri­b­u­tion mod­el for Gilead’s an­tivi­ral remde­sivir, and “hos­pi­tals were in no po­si­tion to give out mon­o­clon­als.”

“We’re get­ting there but it’s tak­en quite a long time,” Wood­cock said in ref­er­ence to the mon­o­clon­al an­ti­bod­ies in the US. “Mass vac­ci­na­tion is hard enough but mass in­fu­sion is a re­al chal­lenge for our health care sys­tem.”

John Far­ley, di­rec­tor of the FDA’s of­fice of in­fec­tious dis­eases, said that the FDA ex­pects to soon broad­en the de­f­i­n­i­tion of who falls in­to the “high risk” cat­e­go­ry that de­ter­mines who can re­ceive the mon­o­clon­al an­ti­bod­ies.

“We know from the field that we would ben­e­fit by broad­en­ing this a bit and we’re ex­pect­ing to do that soon,” he said.

He al­so said that the three au­tho­rized mon­o­clon­al an­ti­bod­ies re­main ac­tive against the vari­ant orig­i­nat­ing in the UK, but there are “oth­er, more wor­ri­some vari­ants” and physi­cians should ex­pect to soon see more in­for­ma­tion on those.

As far as the wider ther­a­peu­tic land­scape for Covid-19, Wood­cock again not­ed the fact that just 5% of clin­i­cal tri­als for Covid-19 treat­ments were ad­e­quate­ly pow­ered and ran­dom­ized to pro­vide ac­tion­able da­ta.

“Low ac­cru­al rates and in­ad­e­quate pow­er mean that safe­ty and ef­fi­ca­cy da­ta will be un­in­ter­pretable,” she said. She al­so crit­i­cized the slow roll­out of the NIH-run tri­als for Covid-19 ther­a­peu­tics.

Over­all, she ex­plained some of the ma­jor chal­lenges that she saw as head of ther­a­peu­tics at Op­er­a­tion Warp Speed, and mov­ing for­ward, she dis­cussed what a ro­bust ecosys­tem for clin­i­cal tri­als in the US would look like.

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Dipal Doshi, Entrada Therapeutics CEO

Ver­tex just found the next big ‘trans­for­ma­tive’ thing for the pipeline — at a biotech just down the street

Back in the summer of 2019, when I was covering Vertex’s executive chairman Jeff Leiden’s plans for the pipeline, I picked up on a distinct focus on myotonic dystrophy Type I, or DM1 — one of what Leiden called “two diseases (with DMD) we’re interested in and we continue to look for those assets.”

Today, Leiden’s successor at the helm of Vertex, CEO Reshma Kewalramani, is plunking down $250 million in cash to go the extra mile on DM1. The lion’s share of that is for the upfront, with a small reserve for equity in a deal that lines Vertex up with a neighbor in Seaport that has been rather quietly going at both of Vertex’s early disease targets with preclinical assets.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ahead of ad­comm, FDA rais­es un­cer­tain­ties on ben­e­fit-risk pro­file of Cy­to­ki­net­ic­s' po­ten­tial heart drug

The FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet next Tuesday to discuss whether Cytokinetics’ potential heart drug can safely reduce the risk of cardiovascular death and heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction.

The drug, known as omecamtiv mecarbil and in development for more than 15 years, has seen mixed results, with a first Phase III readout from November 2020 hitting the primary endpoint of reducing the odds of hospitalization or other urgent care for heart failure by 8%. But it also missed a key secondary endpoint analysts had pegged as key to breaking into the market.

David Light, Valisure CEO

Val­isure in the hot seat: New Form 483 over a 2021 in­spec­tion as CEO fires back

The notorious drug testing company Valisure, which has made a name for itself by forcing FDA’s hand with some of its safety-related uncoverings, received a letter this week after the FDA uncovered violations at its Connecticut-based testing lab in 2021.

The letter, which was sent on Dec. 5, stated that the FDA is “concerned” that Valisure was not aware of  drug supply chain security requirements.

WIB22: Am­ber Salz­man had few op­tions when her son was di­ag­nosed with a rare ge­net­ic dis­ease. So she cre­at­ed a bet­ter one

This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report here.

Amber Salzman’s life changed on a cold, damp day in Paris over tiny plastic cups of lukewarm tea.

She was meeting with Patrick Aubourg, a French neurologist studying adrenoleukodystrophy, or ALD, a rare genetic condition that causes rapid neurological decline in young boys. It’s a sinister disease that often leads to disability or death within just a few years. Salzman’s nephew was diagnosed at just 6 or 7 years old, and died at the age of 12.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.

FDA re­view­ers head back to White Oak in 2023, with lead­er­ship look­ing to ap­pease a new Con­gress

Republicans have taken a stand against the pandemic era habit of lax work-from-home schedules. Now that they’ve wrestled control of the House majority, the FDA’s leadership is playing ball, sending many of the agency’s more than 18,000 employees back to their desks early next year.

Whether this exodus back to White Oak in Silver Spring, MD (many staff will still be allowed to work from home for multiple days per week) will mean more defections to industry and elsewhere remains to be seen.

Bags of shred­ded docs: In­di­an drug­mak­er Lupin hand­ed a Form 483 by FDA in­spec­tors

The generics manufacturer Lupin has been given another Form 483 from the FDA this year.

US regulators inspected Lupin’s pharmaceutical manufacturing site in the town of Mandideep, India from Nov. 14 through Nov. 23, with the 14-page report marking 16 observations.

The inspection report stated that the site did not have the appropriate controls over its computer systems to ensure that changes in “master production” or records are only done by authorized personnel, along with written procedures not being established to conduct annual reviews of records associated with drug batches.

Bro­ken promis­es? FDA needs more pow­er to re­move drugs from mar­ket­place, JA­MA analy­sis finds

The FDA is struggling to remove drugs from the marketplace that don’t show effectiveness in late stage trials, new JAMA analyses found, thanks to the persistent tension between speed and confidence in early clinical data.

Congress, regulated industry and patients have urged the FDA to shorten the amount of time that the market has to wait for drugs to become available that may help severe and prevalent diseases – and the FDA has listened, offering up a quick accelerated approval pathway that’s frequently used by new cancer drugs.

Ab­b­Vie slapped with age dis­crim­i­na­tion law­suit, fol­low­ing oth­er phar­mas

Add AbbVie to the list of pharma companies currently facing age discrimination allegations.

Pennsylvania resident Thomas Hesch filed suit against AbbVie on Wednesday, accusing the company of passing him over for promotions in favor of younger candidates.

Despite 30 years of pharma experience, “Hesch has consistently seen younger, less qualified employees promoted over him,” the complaint states.